Tina Nova

Dr. Tina S.
Nova is an Independent Director at Tang Capital Acquisition Corp., an Independent Director at Azenta, Inc., an Executive Chairman at Exagen, Inc., a Chief Executive Officer & Director at GenomeDx, Inc. (California) and a Venture Partner at Tullis Health Investors, Inc. She is on the Board of Directors at Tang Capital Acquisition Corp., Aurinia Pharmaceuticals, Inc., Azenta, Inc., GenomeDx, Inc. (California), Viridos, Inc., Xequel Bio, Inc., UC San Diego Foundation, University of San Diego and Rady Pediatric Genomics & Systems Medicine Institute.
Dr. Nova was previously employed as a General Manager-Decipher Urologic Cancers by Veracyte, Inc., an Independent Non-Executive Director by Olink Holding AB, a President, Chief Executive Officer & Director by Decipher Biosciences, Inc., an Independent Director by OpGen, Inc., an Independent Director by Veracyte, Inc., a President & Chief Executive Officer by Molecular Stethoscope, Inc., an Executive Vice President & General Manager by Illumina, Inc., an Independent Director by NS Wind Down Co., Inc., an Independent Director by Adamis Pharmaceuticals Corp., an Independent Director by Arena Pharmaceuticals, Inc., a Chairman by Biocom, Inc., a President, Chief Executive Officer & Director by Genoptix, Inc., a President & Chief Operating Officer by Nanogen, a President & Chief Executive Officer by Nanogen, Inc., a Chief Operating Officer by Selective Genetics, Inc., and an Executive Director-New Leads Discovery by Ligand Pharmaceuticals, Inc. She also served on the board at Cypress Bioscience, Inc., Heska Corp.
and CONNECT.
She received her undergraduate degree from the University of California, Irvine and a doctorate degree from the University of California, Riverside.